Milestone Pharmaceuticals Inc
MIST
View Detailed Chart
1.010USD
-0.030-2.88%
Close 03/30, 16:00（ET）Quotes delayed by 15 min
54.03MMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
-2.88%
5 Days
-19.84%
1 Month
-41.62%
6 Months
-49.50%
Year to Date
-50.00%
1 Year
+14.77%
View Detailed Chart
TradingKey Stock Score of Milestone Pharmaceuticals Inc
Currency: USD Updated: 2026-03-27Key Insights
Milestone Pharmaceuticals Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 122 out of 391 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 6.60.In the medium term, the stock price is expected to trend down.Despite a very weak market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Milestone Pharmaceuticals Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Milestone Pharmaceuticals Inc Highlights
StrengthsRisks
Milestone Pharmaceuticals Inc. is a Canada-based biopharmaceutical company. The Company is focused on the development and commercialization of cardiovascular medicines. Its lead product candidate, etripamil, is a potent rapid-onset calcium channel blocker that the Company designed and is developing as a rapid-onset nasal spray to be administered by patients. The Company is also focused on developing etripamil to treat paroxysmal supraventricular tachycardia, atrial fibrillation, and other cardiovascular indications.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 54.60% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 1.55M.
Overvalued
The company’s latest PE is -1.38, at a high 3-year percentile range.
Institutional Buying
The latest institutional holdings are 42.67M shares, increasing 25.46% quarter-over-quarter.
Held by Invesco
Star Investor Invesco holds 21.89K shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of 0.24.
Analyst Rating
Based on
5
analysts
Buy
Current Rating
6.600
Target Price
+473.91%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Milestone Pharmaceuticals Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Milestone Pharmaceuticals Inc Info
Milestone Pharmaceuticals Inc. is a Canada-based biopharmaceutical company. The Company is focused on the development and commercialization of cardiovascular medicines. Its lead product candidate, etripamil, is a potent rapid-onset calcium channel blocker that the Company designed and is developing as a rapid-onset nasal spray to be administered by patients. The Company is also focused on developing etripamil to treat paroxysmal supraventricular tachycardia, atrial fibrillation, and other cardiovascular indications.
Ticker SymbolMIST
CompanyMilestone Pharmaceuticals Inc
CEOOliveto (Joseph)
Websitehttps://www.milestonepharma.com
Related Instruments
+0.96%
+1.56%
+0.85%
+2.90%
-1.28%
+1.78%
+1.47%
+0.07%
+0.00%
+2.70%
-2.08%
-0.13%
+0.72%
+2.03%
+2.33%
0.00%
+1.57%
-0.13%
+2.63%
+2.01%Popular Symbols
246.630
-2.170 (-0.87%)
165.170
-2.350 (-1.40%)
67933.870
+1312.470 (+1.97%)
251.670
-23.670 (-8.60%)
2071.710
+51.010 (+2.52%)
355.280
-6.550 (-1.81%)
4584.740
+73.960 (+1.64%)
101.251
-3.011 (-2.89%)
1.147
+0.001 (+0.09%)
159.668
+0.009 (+0.01%)
